Hemophilia Clinical Trials

21 recruiting

Hemophilia Trials at a Glance

85 actively recruiting trials for hemophilia are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 3 with 16 trials, with the heaviest enrollment activity in Tianjin, Los Angeles, and Seattle. Lead sponsors running hemophilia studies include Institute of Hematology & Blood Diseases Hospital, China, CSL Behring, and Hoffmann-La Roche.

Browse hemophilia trials by phase

Treatments under study

About Hemophilia Clinical Trials

Looking for clinical trials for Hemophilia? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hemophilia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hemophilia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 85 trials

Recruiting
Phase 3

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

Hemophilia AHemophilia B
Pfizer173 enrolled17 locationsNCT05568719
Recruiting
Phase 1Phase 2

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

Hemophilia A
Hoffmann-La Roche5 enrolled2 locationsNCT07226206
Recruiting

Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry

Hemophilia
Institute of Hematology & Blood Diseases Hospital, China100 enrolled2 locationsNCT06992076
Recruiting
Phase 3

SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis

Hemophilia A
Emory University5 enrolled2 locationsNCT04563520
Recruiting
Phase 3

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.40 enrolled18 locationsNCT06922045
Recruiting
Phase 3

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

Hemophilia
Sanofi85 enrolled21 locationsNCT07285460
Recruiting
Phase 1

Lentiviral FVIII Gene Therapy

Hemophilia A
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT03217032
Recruiting
Phase 1

Lentiviral FIX Gene Therapy

Hemophilia B
Shenzhen Geno-Immune Medical Institute10 enrolled1 locationNCT03961243
Recruiting
Phase 3

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

Hemophilia A or B
Suzhou Alphamab Co., Ltd.70 enrolled1 locationNCT07545395
Recruiting

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

Cystic FibrosisHuntington DiseaseSickle Cell Disease+12 more
Assistance Publique - Hôpitaux de Paris550 enrolled1 locationNCT06147414
Recruiting

ATHNdataset Registry

ThrombosisSickle Cell DiseaseHemophilia A+6 more
American Thrombosis and Hemostasis Network200,000 enrolled1 locationNCT06820515
Recruiting
Phase 3

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

Hemophilia B
CSL Behring20 enrolled10 locationsNCT07080905
Recruiting

A Study to Learn More About the Safety of Damoctocog-alfa-pegol When Used in Routine Medical Care in Korean Participants With Hemophilia A

Hemophilia AProphylaxis of BleedingTreatment of Bleeding
Bayer20 enrolled1 locationNCT06222697
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Hemophilia B
Regeneron Pharmaceuticals130 enrolled41 locationsNCT06379789
Recruiting
Phase 3

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Hemophilia AHemophilia B
Pfizer245 enrolled75 locationsNCT05145127
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

Hemophilia A
Hoffmann-La Roche126 enrolled2 locationsNCT07416526
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

Hemophilia A
Hoffmann-La Roche360 enrolled3 locationsNCT07416604
Recruiting

Joint Health, Balance and Quality of Life in Adults With Hemophilia A

Hemophilia A
Yuzuncu Yil University36 enrolled1 locationNCT07523399
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Hemophilia A
Hoffmann-La Roche60 enrolled14 locationsNCT05987449
Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Heart FailurePainInsomnia+22 more
Duke University5,000 enrolled51 locationsNCT04278404